Oral News and Research

RSS

BBB rates 6 Day Dental and Orthodontics A+

6 Day Dental and Orthodontics, a Coppell-based dental company founded by Dr. John Bond in 1989, today announced its A+ rating with the Better Business Bureau (BBB) of Dallas, held since January 2003. BBB assigns grades from A to F with pluses and minuses, and 6 Day has achieved its highest mark. The grade represents BBB's degree of confidence that the business is operating in a trustworthy manner and will make a good faith effort to resolve any customer concerns.

19 Jan 2010

Effects of obesity, smoking and drinking on natural and medically assisted reproduction

The European Society of Human Reproduction and Embryology (ESHRE) has published a position statement on the impact of the life style factors obesity, smoking and alcohol consumption on natural and medically assisted reproduction.

19 Jan 2010

Seven out of eight Swedish adolescents have poor oral hygiene

Swedish 19-year-olds need to improve their oral hygiene habits. Seven out of eight adolescents have unacceptable oral hygiene, which increases the risk of future dental problems. These are the findings of a new study from the Sahlgrenska Academy at the University of Gothenburg.

19 Jan 2010

Enrollment of Phase 2 portion of Cempra Pharmaceuticals' Phase 2/3 clinical trial of TAKSTA completed

Cempra Pharmaceuticals today announced completion of enrollment of the Phase 2 portion of its Phase 2/3 clinical trial of TAKSTA (sodium fusidate; CEM-102) for the treatment of acute bacterial skin and skin structure infections.

19 Jan 2010

Psoriasis therapy costs outpace inflation

Findings from a cost model suggest that expenses for systemic psoriasis therapy appear to be increasing at a faster rate than inflation, and newer biologically derived treatments are more expensive than traditional systemic therapies, according to a report in the January issue of Archives of Dermatology, one of the JAMA/Archives journals.

19 Jan 2010

Hyperphosphatemia following standard OSP doses is related to weight, reveals study

Colon cleansing is used widely for colonoscopic exploration and colonic and gynecological surgery. Oral sodium phosphate (OSP) solution is the osmotic laxative most commonly used for this purpose. It is known that OSP can induce severe hyperphosphatemia and hypocalcemia due to excessive absorption of phosphates, and there have been reports of deaths and irreversible dialysis-requiring renal insufficiency. However, no prospective studies have investigated the prevalence of hyperphosphatemia in low-risk patients.

18 Jan 2010

MAGIC investigators identify new genetic variants that influence insulin and glucose regulation

An international research consortium has found 13 new genetic variants that influence blood glucose regulation, insulin resistance, and the function of insulin-secreting beta cells in populations of European descent. Five of the newly discovered variants increase the risk of developing type 2 diabetes, the most common form of diabetes.

18 Jan 2010

Researchers uncover novel genetic markers for diabetes-related traits

In two major studies published in Nature Genetics today, researchers use biological understanding to dissect the genetics of diabetes. An international team comprising researchers from more than 100 institutions analysed vast suites of genetic data from more than 100,000 people of European descent to uncover the associations.

18 Jan 2010

Advantages of dental implants

Dental implants, rather than a fixed bridge or removable dentures, are an increasingly popular method of replacing teeth lost to an accident, gum diseases or tooth decay.

18 Jan 2010

Results from Bionovo's phase 1B clinical trial of Bezielle published

Bionovo, Inc. announced today the publication of their results from its phase 1B clinical trial of Bezielle (BZL101) for metastatic breast cancer. The results of the study are available online in Breast Cancer Research and Treatment and demonstrate that Bezielle continues to be safe and well tolerated with clinical evidence of anticancer activity in a heavily pretreated population of women diagnosed with metastatic breast cancer.

17 Jan 2010

Genomic and Personalized Medicine Conference in USA

Elsevier announced today the Genomic and Personalized Medicine Conference in Arlington, VA, USA from May 16-18, 2010, which is, supported by The Lancet and organized in association with the book 'Genomic and Personalized Medicine.

13 Jan 2010

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

Emisphere Technologies, Inc. today announced that Novo Nordisk has initiated its first Phase I clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a $2 million payment to Emisphere, whose proprietary Eligen® Technology is used in the formulation of NN9924.

13 Jan 2010

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug’s bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.

13 Jan 2010

Autologous stem cell transplantation may benefit breast cancer patients

Compared to conventional chemotherapy, autologous stem cell transplantation can extend "event-free survival" for breast cancer patients. Clinical trials provide proof of this for breast cancer with and without distant metastases. However, there are indications that this type of stem cell transplantation can more frequently give rise to severe complications affecting almost all organ systems. This is the conclusion of the final report of the Institute for Quality and Efficiency in Health Care (IQWiG) published on 16 December 2009.

13 Jan 2010

Coalition asks Congress to eliminate excise tax on health benefits

American Dental Association President Ron Tankersley, DDS, says the provision as written, "[I]s the opposite of health care reform. It would compel many employers to drop critical dental and other coverage to avoid the tax. It dismantles exactly the type of preventive, primary care that everyone agrees this country needs more of."

13 Jan 2010

BDSI to discuss planned BEMA Granisetron IND with the FDA

BioDelivery Sciences International, Inc. announced that the company has been granted a meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned Investigational New Drug (IND) application for BDSI’s antiemetic (anti-nausea and vomiting) product candidate, BEMA Granisetron. The meeting will take place on March 17, 2010. The company will discuss with the FDA clinical development and regulatory plans for BEMA Granisetron, which is anticipated to enter Phase 1 studies in the second quarter of 2010.

13 Jan 2010

Patient enrollment in Spherix's global Phase 3 clinical trial NEET completed

Spherix Inc., an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced the completion of patient enrollment in its global Phase 3 clinical trial NEET (70971-004), which is evaluating the safety and efficacy of D-tagatose as an oral treatment for Type 2 diabetes mellitus.

12 Jan 2010

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

TGen Drug Development (TD2) and Critical Outcome Technologies Inc. (COTI) (TSXV:COT) announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.

12 Jan 2010

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

NanoViricides, Inc. (the "Company"), reports that the Company has been invited to present on January 12th at the Biotech Showcase™, a conference designed to showcase promising companies and technologies for partnering and investment purposes.

12 Jan 2010

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Human Genome Sciences, Inc. today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.

12 Jan 2010

Oral News and Research

BBB rates 6 Day Dental and Orthodontics A+

Effects of obesity, smoking and drinking on natural and medically assisted reproduction

Seven out of eight Swedish adolescents have poor oral hygiene

Enrollment of Phase 2 portion of Cempra Pharmaceuticals' Phase 2/3 clinical trial of TAKSTA completed

Psoriasis therapy costs outpace inflation

Hyperphosphatemia following standard OSP doses is related to weight, reveals study

MAGIC investigators identify new genetic variants that influence insulin and glucose regulation

Researchers uncover novel genetic markers for diabetes-related traits

Advantages of dental implants

Results from Bionovo's phase 1B clinical trial of Bezielle published

Genomic and Personalized Medicine Conference in USA

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

Autologous stem cell transplantation may benefit breast cancer patients

Coalition asks Congress to eliminate excise tax on health benefits

BDSI to discuss planned BEMA Granisetron IND with the FDA

Patient enrollment in Spherix's global Phase 3 clinical trial NEET completed

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News